From: USP4 function and multifaceted roles in cancer: a possible and potential therapeutic target
Authors, year | Pathophysiologic processes | Deubiquitinated targets | Effects to the deubiquitinated targets | Detailed mechanisms | Refs. |
---|---|---|---|---|---|
Zhu et al., 2018 | Liver fibrosis | TβRI | Stabilization | HSC and EMT activation; liver fibrosis enhancement | [51] |
Zhao et al., 2018 | NAFLD pathogenesis | TAK1 | Inactivation | Alleviation NAFLD progression through inactivation of NF-κB and JNK signaling pathways | [53] |
Zhou et al., 2019 | Hepatic I/R injury | TAK1 | Inactivation | Alleviation hepatic I/R injury by inhibiting inflammatory caused by NF-κB signaling pathway | [54] |
Zhou et al., 2012 | Innate immune response and immune homeostasis | TRAF6 | Inactivation | Inhibition of the immunoinflammatory response caused by TLR/IL-1R-induced NF-κB activation | [56] |
Yang et al., 2015 | Th17 cell function | RORγt | Stabilization | IL-17 expression upregulation | [57] |
Lin et al., 2017 | Treg cell function | IRF8 | Stabilization | Enhancement of IL-10, TGF-β expression to promote Treg cell function | [60] |
Guo et al., 2017 | Th2 cell function | IRF4 | Stabilization | Enhancement of IL-4 expression to promote Th2 cell function | [61] |
Jiang et al., 2017 | Spinal cord injury | TRAF6 | Inactivation | Inhibition of secondary spinal cord injury through NF-κB inactivation | [63] |
Wang et al., 2013 | Antiviral response | RIG-I | Stabilization | Activation of RIG-I-induced IFN-β signaling pathway and VSV replication inhibition | [70] |
Xu et al., 2018 | Antiviral response | TRAF6 | Stabilization | Activation of TRAF6-mediated NF-κB signaling pathway and EV 71 replication inhibition | [71] |
Wijinhoven et al., 2015 | DNA breaks repairment | USP4 | Stabilization | DNA repairment enhancement | [73] |
Zhou et al., 2016 | Osteoblast differentiation | Dvl | Inactivation | Inhibition of Wnt/β-catenin signaling pathway mediated osteoblast differentiation | [80] |
Yun et al., 2017 | Myogenesis | HDAC1 and 4 | Stabilization | Enhancement of MyoD to inhibit myogenesis | [82] |
He et al., 2016 | Pathological cardiac hypertrophy | TAK1 | Inactivation | Inactivation of TAK1/JNK1/2/p38 to inhibit pathological cardiac hypertrophy | [83] |